Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUnidade Local de Saude do Nordeste
About this trial
Clinical trial
The goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:
* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant * What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery
Participants will:
* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol. * Monitoring will be continuous in the ICU
Eligibility criteria
Qualifiers
Written informed consent for participation in the study
Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)
Total bilirubin ≥ 12 mg/dL and INR ≥ 1.5
On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy
Disqualifiers
Refusal to provide consent
Pregnancy
Expected survival < 24 hours due to disease severity (hemodynamic instability requiring norepinephrine > 0.20 mcg/kg/min and/or mechanical ventilation with PaO₂/FiO₂ < 150 and/or non-hepatic coma)
ACLF severity greater than CLIF-C ACLF grade 3
Trial design
Treatments tested in this trial
- DPMAS plus plasma exchange
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov